You are on page 1of 29

PMIDOWN STATDA DCOMIS IS VI DP TI triad

21108852 NLM MEDLINE 20101223 20110131 1743-422X (Electronic) 1743-422X (Linking) 7 2010 Hepatitis C virus, human immunodeficiency virus and Pseudomonas phage PS5

share epitopes of immunogenic determinants. PG - 346 AB - A lytic phage for Pseudomonas aeruginosa belongs to the Myoviridea family was isolated from urine for use in therapeutics. Pair of hepatitis C virus (HC V) primers highlighted segments on the genome of this phage. The sequence of these PCR products as well as the possible serological cross reactivity/relation ship between HCV and the phage were investigated. One hundred HCV positive huma n sera were analyzed by ELISA. Ninety six well plates were coated with multiple e pitopes of HCV proteins (Kit), phage and Pseudomonas cells. Initially the positive and negative control sera supplied in the test kit were used to evaluate the c ross reactivity between the phage and anti-HCV antibodies. The results suggeste d a value over than 0.105 for a HCV positive reaction. Of the 100 HCV positive sera tested, sixty five and thirty percent showed cross reaction with phage lys ate and Pseudomonas aeruginosa, respectively. High HCV antibody titer correlated t o high cut off value for phage cross reaction, whereas no such correlation existe d between HCV antibody titer and Pseudomonas cross reaction. The PCR product s were sequenced and aligned with the HCV genome of H77. Sequence homology was de tected in the 5', 3' UTRs and NS3 regions. Further these products showed similari ty with HIV-1 Env, Pol & 3'LTR regions as well. AD - No.102, Department of Microbiology, University of Karachi, Karachi, Pakist an. zhabizg@yahoo.com FAU - Golkar, Zhabiz AU - Golkar Z FAU - Jamil, Nusrat AU - Jamil N LA - eng PT - Journal Article DEP - 20101126 PL - England TA - Virol J JT - Virology journal JID - 101231645

RN RN RN RN RN SB MH MH MH MH MH MH MH MH MH MH MH MH MH MH MH PMC OID EDATMHDACRDTPHSTPHSTPHSTAID AID PST SO -

0 (DNA, Viral) 0 (Epitopes) 0 (Hepatitis C Antibodies) 0 (RNA, Viral) 0 (Viral Proteins) IM *Cross Reactions DNA, Viral/genetics Epitopes/*immunology Female HIV-1/genetics/*immunology Hepacivirus/genetics/*immunology Hepatitis C Antibodies/*immunology Humans Pseudomonas Phages/genetics/*immunology Pseudomonas aeruginosa/immunology RNA, Viral/genetics Sequence Analysis, DNA Sequence Homology Viral Proteins/*immunology Young Adult PMC3006387 NLM: PMC3006387 2010/11/27 06:00 2011/02/01 06:00 2010/11/27 06:00 2010/05/13 [received] 2010/11/26 [accepted] 2010/11/26 [aheadofprint] 1743-422X-7-346 [pii] 10.1186/1743-422X-7-346 [doi] epublish Virol J. 2010 Nov 26;7:346.

PMID- 21108831 OWN - NLM STAT- MEDLINE DA - 20101224 DCOM- 20110131 IS - 1743-422X (Electronic) IS - 1743-422X (Linking) VI - 7 DP - 2010 TI - CD26/dipeptidyl peptidase IV (CD26/DPPIV) is highly expressed in periphera l blood of HIV-1 exposed uninfected female sex workers. PG - 343 AB - BACKGROUND: Design of effective vaccines against the human immunodeficienc y virus (HIV-1) continues to present formidable challenges. However, individuals w ho are exposed HIV-1 but do not get infected may reveal correlates of protection that may inform on effective vaccine design. A preliminary gene expression anal ysis of HIV resistant female sex workers (HIV-R) suggested a high expression CD26/ DPPIV gene. Previous studies have indicated an anti-HIV effect of high CD26/DPPI V expressing cells in vitro. Similarly, high CD26/DPPIV protein levels in vi

AD . Adrienne F A AU . Joshua AU . CONCLUSION: HIV resistant sex workers have a high expression of CD26/DPPIV in tandem with lowered immune activation markers.Kimani.Wachihi.Luo. a central mediator of the immune response and activator of HIV-1 transcripti on.Centre For Virus Research.Songok EM FAU . Ma AU . p < 0. Nairobi.Rono.Kimani J FAU . Blake T .90 p = 0.30% vs 82. Similarly a FACs analysis of cell associated DPPIV (CD26) revealed a higher CD26/DPPIV expression on CD4+ Tcells derived from HIV-R than from the HIV+ (90.McKinnon.Apidi. Martin K AU .30% vs 80. Bernard AU . An evaluation for hyperglycemia. RESULTS: A quant itative CD26/DPPIV plasma analysis from 100 HIV-R.30 p < 0.001).Luo M FAU . We carried out a study to confirm if the high CD26/DPPIV gene expression among the HIV-R were concor dant with high blood protein levels and its correlation with clinical type 2 di abetes and other perturbations in the insulin signaling pathway.Songok. Lyle AU .Wachihi C FAU .Apidi W FAU .ca FAU . Elizabeth J AU . did not confirm Type 2 diabetes but an impai red fasting glucose condition (5. A further comparison of the mean fluorescent intensity (MFI) of CD26/DPPIV expression showed a higher DPP4 MFI on HIV-R CD4+ T cells (median 118 vs 91 for HIV-Neg. Mbagathi Road Kenya Medical Research Institute. p = 0.McKinnon L FAU . A follow-up quantitative PCR ana lysis of the insulin signaling pathway genes showed a down expression of NFkappa B.0003).Osero.001) respectively.Matey EJ FAU .Matey.umanitoba.Ball.Meyers.002) and HIV Neg controls (90. Charles AU .Meyers AF FAU . Elijah M AU .Osero B FAU . 100 HIV infected (HIV +) and 10 0 HIV negative controls (HIV Neg) showed a significantly elevated CD26/DPPIV concentration among the HIV-R group (mean 1315 ng/ml) than the HIV Neg (91 0 ng/ml) and HIV + (870 ng/ml.Rono MK FAU .775 mmol/L). Winnie AU . Songok@cc. This may suggest a novel ro le for CD26/DPPIV in protection against HIV infection in vivo. Kenya.vo have been shown to be a risk factor for type 2 diabetes.

7:343.5 (DPP4 protein.4.14. Frank A Plummer FA Mpoke. Gov't 20101125 England Virol J Virology journal 101231645 0 (NF-kappa B) EC 3. Solomon Mpoke S eng Journal Article Research Support. and RNAi of BTBD2 in old world monkey human cells increases permissiveness to HIV-1 infection. human) EC 3. 2010 Nov 25.332 AB . Non-U.1186/1743-422X-7-343 [doi] epublish Virol J. PG . 21092135 NLM MEDLINE 20101217 20110131 1743-422X (Electronic) 1743-422X (Linking) 7 2010 Human TOP1 residues implicated in species specificity of HIV-1 infection a required for interaction with BTBD2.5 (Dipeptidyl Peptidase 4) IM CD4-Positive T-Lymphocytes/*chemistry Dipeptidyl Peptidase 4/analysis/*blood Female Gene Expression Profiling HIV/*immunology HIV-1/*immunology Humans *Immunity. TRIM5alpha restricts HIV-1 .AU FAU AU FAU AU LA PT PT DEP PL TA JT JID RN RN RN SB MH MH MH MH MH MH MH MH MH MH PMC OID EDATMHDACRDTPHSTPHSTPHSTAID AID PST SO PMIDOWN STATDA DCOMIS IS VI DP TI re and Ball BT Plummer.BACKGROUND: Host determinants of HIV-1 viral tropism include factors from producer cells that affect the efficiency of productive infection and fact ors in target cells that block infection after viral entry.14. Innate NF-kappa B/biosynthesis *Prostitution PMC3009705 NLM: PMC3009705 2010/11/27 06:00 2011/02/01 06:00 2010/11/27 06:00 2010/09/14 [received] 2010/11/25 [accepted] 2010/11/25 [aheadofprint] 1743-422X-7-343 [pii] 10.4.S.

infection at an early post-entry step through a mechanism associated with rapid disassembly of the retroviral capsid.Journal Article PT . Uniformed Services University of the Health Scien ces.Stantchev TS FAU . Tzanko S AU . Mary Lou AU . FAU .D'Arpa P LA . Because BTBD1 and BTBD2 interact with one HIV-1 viral tropism factor.. Peter AU . Additionally.eng GR . AD . USA. and co-localize with a splice variant of another.Zhuang L FAU . N. 4301 Jones Bridge Road.Khurana. as the expression of human TOP1 in African Green Monkey (AGM) virion-producing cells increased the infectivit y of progeny virions by five-fold.Broder. interference with the expression of BTBD2 in AGM and human 293T target cells increased their permissiveness to HIV-1 infect ion two.Research Support. Prasun K AU .Moitra. Our previous studies showed that TO P1 interacts with BTBD1 and BTBD2.Zhuang.H. we investigated the potential involvement of BT BD1 and BTBD2 in HIV-1 restriction.to three-fold.20101120 PL .R01CA059750/CA/NCI NIH HHS/United States PT . Bethesda. This infectivity enhancement required human TOP1 residues 236 and 237 as their replacement with the AGM counterpart residue s abolished the infectivity enhancement. TOP1. Topoisomerase I (TOP1) appears to pl ay a role in HIV-1 viral tropism by incorporating into or otherwise modulating virions affecting the efficiency of a post-entry step.Khurana B FAU .Department of Pathology.Cutler ML FAU .I.Moitra PK FAU . Lei AU . the same residues r equired to enhance the infectivity of progeny virions when hu-TOP1 is expressed in AGM producer cells.Broder CC FAU . Extramural DEP . CONCLUSIONS: These results do not exclude the possibil ity that BTBD2 may modestly restrict HIV-1 infection via colocation with TRIM5 variants in cytoplasmic bodies.Cutler.Stantchev. RESULTS: We show that the interaction of BTBD1 and BTBD2 with TOP1 requires hu-TOP1 residues 236 and 237. Bharat AU . MD 20814.D'Arpa. two proteins which co-localize with the TRIM5alpha splice variant TRIM5delta in cytoplasmic bodies. Christopher C AU .England .

1.99.Congresses PT .S327-86 LA .Overall PL . Molecular *Protein Interaction Mapping Transcription Factors/metabolism PMC3002306 NLM: PMC3002306 2010/11/26 06:00 2011/02/01 06:00 2010/11/25 06:00 2010/05/15 [received] 2010/11/20 [accepted] 2010/11/20 [aheadofprint] 1743-422X-7-332 [pii] 10. Win nipeg. Canada.2 (TOP1 protein.21038473 OWN . November 2009. PMID.United States TA . PG . Type I) EC 5.AIM SB . human) 0 (BTBD2 protein.202 Suppl 3 DP .7:332.eng PT .IM MH .1537-6613 (Electronic) IS .1.TA JT JID RN RN RN RN RN RN RN SB MH MH MH MH MH MH MH MH MH MH MH MH MH PMC OID EDATMHDACRDTPHSTPHSTPHSTAID AID PST SO - Virol J Virology journal 101231645 0 (BTBD1 protein.2 (DNA Topoisomerases.MEDLINE DA .Proceedings of the International Symposium on Natural Immunity to HIV. human) IM Animals Carrier Proteins/antagonists & inhibitors/*metabolism Cell Line Cercopithecus aethiops DNA Topoisomerases.1186/1743-422X-7-332 [doi] epublish Virol J. human) 0 (Carrier Proteins) 0 (DNA-Binding Proteins) 0 (Transcription Factors) EC 5.0022-1899 (Linking) VI .20101029 DCOM. 2010 Nov 20.J Infect Dis JT .0413675 SB .NLM STAT.2010 Nov 1 TI .20101101 IS .99.The Journal of infectious diseases JID . Manitoba. Type I/*metabolism DNA-Binding Proteins/metabolism Gene Silencing HIV-1/*immunology/physiology *Host Specificity Humans Models.HIV/*immunology .

1539-6509 (Linking) VI .Research Support.Discov Med JT . but more recently in hum ans.NLM STAT. University of Tennessee..R01 CA71971/CA/NCI NIH HHS/United States GR .R01 EY05093/EY/NEI NIH HHS/United States PT .edu FAU .United States TA . PMID.MEDLINE DA .IM . N. In this review.21034678 OWN .Rouse.53 DP .H. Tennessee 37996. College of Veterinary Medicine.MH MH MH EDATMHDACRDTPST SO - HIV Infections/*immunology Humans Immunity. Barry T AU .Review PL . PG .202 Suppl 3:S327-86. we highlight some of the major challenges we face in unrav eling this complexity and summarize current efforts under way to improve the eff icacy of viral vaccines. AD .R01 CA139220/CA/NCI NIH HHS/United States GR . Major strides have been made in our understanding of innate and adaptive immune responses to viruses. largely based on highly reductionistic animal infection models.R01 AI106336501/AI/NIAID NIH HHS/United States GR . USA.Department of Pathobiology. 2010 Nov 1.Rouse BT FAU .363-70 AB . with validation that fundamental immunological concepts do in fact transla te into clinical science well.Lukacher AE LA .Discovery medicine JID .Some unmet challenges in the immunology of viral infections.10 IP .20101101 DCOM.2010 Oct TI .0 (Viral Vaccines) SB . Aron E AU .eng GR .20110202 IS .Journal Article PT . Knoxville. Extramural PT .Viral immunology is a rapidly evolving field.Lukacher. btr@utk.1944-7930 (Electronic) IS .I. Innate 2010/11/03 06:00 2010/11/03 06:01 2010/11/02 06:00 ppublish J Infect Dis.101250006 RN . From these studies there has emerged an appreciatio n of the enormous complexity of the immune response to viral infections as well as the diverse array of strategies developed by viruses to deal with immune detec tion.

Hoots. Maryland. Frederick.Hoots WK . James J AU . 384 with HBV recovery. Laboratory of Experimental Immunology. FAU . To assess whet her the polymorphism marking the haplotype (rs12979860) also affects other interferon-alpha responsive chronic viral illnesses. H1N1 Subtype/immunology Treatment Outcome Vaccination/methods Viral Vaccines/immunology/therapeutic use Virus Diseases/*immunology/*therapy Viruses/*immunology 2010/11/03 06:00 2011/02/03 06:00 2010/11/02 06:00 ppublish Discov Med.MH MH MH MH MH MH MH MH MH MH EDATMHDACRDTPST SO PMIDOWN STATDA DCOMIS IS VI IP DP TI - HIV/immunology Hepacivirus/immunology Humans Immunity.99).Martin. Maureen P AU . resistance to HIV infection (odds ratio. AD . and 2548 with or at high risk for HIV infection.1749-53 AB . The C/C genotype of rs12979860 was not associated with HBV recovery (odds ratio. Ying AU . or HIV disease progression (P > .Hussain SK FAU .Qi Y FAU . PG .Goedert. we genotyp ed 226 individuals with HBV persistence. USA. namely hepatitis B vi rus (HBV) and human immunodeficiency virus (HIV) type 1 infections.Qi. Gregory D AU . Shehnaz K AU . Innate/physiology Influenza A Virus. This IL28B single-nucleotide polymor phism affects the immune response to HCV but not to HBV or HIV. W Keith AU .97). SAIC-Frederick.05). 0. NCI-Frederick.Martin MP FAU . 0.10(53):363-70.Kirk. 20977343 NLM MEDLINE 20101104 20101210 1537-6613 (Electronic) 0022-1899 (Linking) 202 11 2010 Dec 1 IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection.An IL28B haplotype strongly determines the outcome of natural and interferon-alpha treated hepatitis C virus (HCV) infection. 2010 Oct.Cancer and Inflammation Program.Kirk GD FAU .Hussain.Goedert JJ FAU .

.I.H. U.H. N..S. Non-U.H.S. Chloe L Thio CL eng 5-MO1-RR-00722/RR/NCRR NIH HHS/United States MO1-RR00059/RR/NCRR NIH HHS/United States MO1-RR00071/RR/NCRR NIH HHS/United States MO1-RR02558/RR/NCRR NIH HHS/United States MO1-RR06020/RR/NCRR NIH HHS/United States N01-CO-12400/CO/NCI NIH HHS/United States N01-HD-4-3200/HD/NICHD NIH HHS/United States N02-CP-55504/CP/NCI NIH HHS/United States R01-DA-04334/DA/NIDA NIH HHS/United States R01-DA-12568/DA/NIDA NIH HHS/United States R01-HD-4-1224/HD/NICHD NIH HHS/United States UO1-AI-35039/AI/NIAID NIH HHS/United States UO1-AI-35040/AI/NIAID NIH HHS/United States UO1-AI-35041/AI/NIAID NIH HHS/United States UO1-AI-35042/AI/NIAID NIH HHS/United States UO1-AI-35043/AI/NIAID NIH HHS/United States UO1-AI-37613/AI/NIAID NIH HHS/United States UO1-AI-37984/AI/NIAID NIH HHS/United States Journal Article Research Support.I. Intramural Research Support. P. Mary Carrington M Thio.FAU AU FAU AU FAU AU LA GR GR GR GR GR GR GR GR GR GR GR GR GR GR GR GR GR GR PT PT PT PT PT DEP PL TA JT JID RN RN SB SB MH MH MH MH MH MH MH MH MH MH MH MH MH MH MH MH MH PMC MID OID OID - Buchbinder. Gov't. Susan Buchbinder S Carrington. Single Nucleotide Proportional Hazards Models Young Adult PMC2974014 NIHMS233857 NLM: NIHMS233857 [Available on 12/01/11] NLM: PMC2974014 [Available on 12/01/11] . human) 0 (Interleukins) AIM IM Adult Case-Control Studies Cohort Studies Female Genotype HIV Infections/*immunology HIV-1/*immunology Hepacivirus Hepatitis B/*immunology Hepatitis B virus/*immunology Hepatitis C Humans Interleukins/*genetics/immunology Male *Polymorphism. 20101026 United States J Infect Dis The Journal of infectious diseases 0413675 0 (IL28B protein. Extramural Research Support. Gov't Research Support. N.S.

Epub 2010 Oct 26.1172/JCI44872 [doi] 44872 [pii] Individuals infected with HIV-1 progress to AIDS at different rates.1086/657146 [doi] ppublish J Infect Dis. AD .S. PG LID LID AB ith 2010/10/28 06:00 2010/12/14 06:00 2010/10/28 06:00 2011/12/01 2010/10/26 [aheadofprint] 10. Tumor and Cell Biology.0 (Antibodies. CD) .0 (Antigens.Chiodi F LA .20101025 PL . In this issue of the JCI. compared w approximately 10 years in typical progressors. Rapid progressors develop AIDS within 2-5 years of initial infection.7802877 RN . Sweden. Francesca AU .se FAU . Stockholm.Journal Article PT . Non-U. Depletion was mediated by programmed death-1 (PD-1) and resulted in reduction of antibody titers spe cific for SIV and bacterial antigens. Progression to AIDS is asso ciated with impaired humoral and cellular immunity.The Journal of clinical investigation JID .eng PT . Interestingly.Department of Microbiology.Research Support. Gov't DEP . francesca.United States TA . 2010 Dec 1.J Clin Invest JT .202(11):1749-53. 20972328 NLM MEDLINE 20101102 20101207 20110103 1558-8238 (Electronic) 0021-9738 (Linking) 120 11 2010 Nov 1 New therapy to revert dysfunctional antibody responses during HIV-1 infect 3810-3 10.Chiodi.EDATMHDACRDTPMCRPHSTAID PST SO PMIDOWN STATDA DCOMLR IS IS VI IP DP TI ion. Viral) RN . These findings pave the way for a new therapeutic str ategy aimed at improving humoral immunity in HIV-1 infection. Karolinska Institutet. Tit anji and colleagues report that activated memory B (mBAct) cells are depleted i n SIV-infected macaques defined as rapid progressors. blockade of PD-1 in infecte d animals protected B cells from apoptosis and increased levels of SIV-speci fic antibodies in blood.chiodi@ki.Comment PT .

The goal of this study was to evaluate the utility of Calypte AWARE HIV-1/2 OMT antibody test as a screening test in an India n setting. Blood was collected a nd tested from these clients for HIV diagnosis as per routine policy and the . 20966557 NLM MEDLINE 20101022 20110214 1998-3646 (Electronic) 0255-0857 (Linking) 28 4 2010 Oct-Dec Evaluation of Calypte AWARE HIV-1/2 OMT antibody test as a screening test Indian setting. Oral fluid tests provide a n alternative for people who do not want blood to be drawn.1172/JCI44872. it avoids the risk of occupational exposure.PURPOSE: Integrated counselling and testing centres (ICTC) provide counsel ling and blood testing facilities for HIV diagnosis. doi: 10. PG .295-8 AB . Viral/blood/immunology *Antibody Formation Antigens. Also. CD/immunology CD8-Positive T-Lymphocytes/immunology Cell Differentiation Cell Survival *HIV Infections/drug therapy/immunology/physiopathology HIV-1/*immunology Humans Immunologic Memory/*immunology Lymphoid Tissue/cytology/immunology *Simian Acquired Immunodeficiency Syndrome/drug therapy/immunology/physiopathology Simian immunodeficiency virus/*immunology PMC2965000 NLM: PMC2965000 2010/10/26 06:00 2010/12/14 06:00 2010/10/26 06:00 2010/10/25 [aheadofprint] 44872 [pii] 10. MATERIALS AND METHODS: A cross-sectional study was carried out af ter ethics committee approval in 250 adult ICTC clients. 2010 Nov 1.120(11):3810-3. PMID: 20972331 Animals Antibodies.1172/JCI44872 [doi] ppublish J Clin Invest. Epub 2010 25.120(11):3878-90. 2010 Nov 1.SB SB CON MH MH MH MH MH MH MH MH MH MH MH MH MH - MH PMC OID EDATMHDACRDTPHSTAID AID PST SO Oct PMIDOWN STATDA DCOMIS IS VI IP DP TI in an AIM IM J Clin Invest.

Bande.Mehta. after another written informed consent. Seventy six percent of clients preferred oral fluid testing.05). Diagnostic MH . CONCLUSION: Oral fluid testing can be used as a screening test for HIV diagnosis. Twenty five clients who had and 25 clients who had not com pleted their secondary school education (Group A and Group B.Predictive Value of Tests MH . PPV and NPV of the oral fluid antibody test were 100%.AIDS Serodiagnosis/methods MH . oral fluid was collected from the clients and tested for the pres ence of HIV antibodies. 98.0 (Reagent Kits. R N AU . Seth GSMC & KEMH.Male MH .Mass Screening/*methods MH . P R AU .Journal Article PL .Wanjare.Paranjpe SM FAU .HIV Infections/*diagnosis/immunology/prevention & control/virology MH . AD .Evaluation Studies PT . N A AU .0 (HIV Antibodies) RN . specificity. S W AU .Paranjpe. however. Parel. nayanaingole@gmail.Mehta PR FAU .Wanjare SW LA .Indian journal of medical microbiology JID . respectively) were also asked to perform and interpret the test on their own and their findings an d experiences were noted.Bande RN FAU .Cross-Sectional Studies MH .India MH .Sensitivity and Specificity EDAT. 94.eng PT .Saliva/*immunology MH . Diagnostic) SB .Indian J Med Microbiol JT .11% and 100%.Ingole. S M AU . Mumbai.Department of Microbiology. respectively.IM MH .51%.results were considered as the gold standard.com FAU .Adult MH .Ingole NA FAU . Group B found it difficult to perform the test as compared to Group A and this difference w as statistically significant (P </= 0. RESULT: The sensitivity.HIV-2/*immunology MH .HIV-1/*immunology MH . Also. India.8700903 RN . confirmation of react ive results by blood-based tests is a must.India TA .2010/10/23 06:00 .Humans MH .HIV Antibodies/analysis/*blood MH .Reagent Kits.

290-4 AB . fro m 7. followed by HIV-1 subtype B and HIV-1 subtype A. Sample from 1 positive partner was detected as subt ype C by env HMA and subtype B by gag sequencing. Setting: Integrated Counselling and Testing Centre (ICTC). and subtype A. b) willingness of both partners to provide w ritten informed consent including consent to continued couple counselling for 3 m onths. from 2. and DNA sequencing by amplifying gag region.MHDACRDTAID AID PST SO PMIDOWN STATDA DCOMIS IS VI IP DP TI - 2011/02/15 06:00 2010/10/23 06:00 IndianJMedMicrobiol_2010_28_4_295_71809 [pii] 10. AD . and both env and gag gene were amplified successfu lly in 5/30 samples. Seth GSMC & KEM Hospital. Participants: Thirty HIV-1 serodiscordant couples. RESULTS: HIV-1 env gene was amplified successfully in 10/30 sample s.AIMS: To determine the prevalent subtypes of HIV-1 in serodiscordant coupl es. . Department of Microbiology. in 25/30 samples. 20966556 NLM MEDLINE 20101022 20110214 1998-3646 (Electronic) 0255-0857 (Linking) 28 4 2010 Oct-Dec Study of HIV-1 subtypes in serodiscordant couples attending an integrated counselling and testing centre in Mumbai using heteroduplex mobility analy sis and DNA sequencing. India.71809 [doi] ppublish Indian J Med Microbiol. PG .4103/0255-0857. current history of co ntinued unprotected sexual activity within the partnership. subtype B. respectively. STUDY DESIGN: Prospective pilot study. DNA sequencing was found to be the most reliable method for determining the su btypes of HIV-1. Mumbai. gag gene.28(4):295-8. MATERIALS AND METHODS: HIV-1 subtyping was carried out by heteroduplex mob ility analysis (HMA) by amplifying env region. INCLUSION CRITERIA: a) Documentation of HIV-1 infe ction in one partner and seronegative status in the other. CONCLUSION: HIV-1 subtype C wa s found to be the predominant subtype of HIV-1 in serodiscordant couples attending our ICTC. demonstration that the y have been in a partnership for at least 1 year and are not currently on highly active antiretroviral therapy HAART.Department of Microbiology. 2010 Oct-Dec. HIV-1 subtype C was detected from 21 samples.

G Nataraj G eng Evaluation Studies Journal Article India Indian J Med Microbiol Indian journal of medical microbiology 8700903 0 (DNA.kem@gmail. Viral/analysis/genetics Delivery of Health Care. env Genes. Integrated *Family Characteristics Female Genes.FAU AU FAU AU FAU AU FAU AU FAU AU FAU AU LA PT PT PL TA JT JID RN SB MH MH MH MH MH MH MH MH MH MH MH MH MH MH MH MH MH MH EDATMHDACRDTAID AID PST SO PMIDOWN STATDA DCOMIS IS VI DP TI th prm.28(4):290-4. Hospital Prevalence Sequence Analysis. 20946627 NLM MEDLINE 20101102 20101201 1743-422X (Electronic) 1743-422X (Linking) 7 2010 Anti-HIV-1 activity of salivary MUC5B and MUC7 mucins from HIV patients wi different CD4 counts. S Nema S Paranjpe. DNA/*methods 2010/10/23 06:00 2011/02/15 06:00 2010/10/23 06:00 IndianJMedMicrobiol_2010_28_4_290_71807 [pii] 10. .71807 [doi] ppublish Indian J Med Microbiol. S Wanjare S Nataraj. gag HIV Infections/epidemiology/*virology *HIV Seronegativity HIV-1/*classification/*genetics/immunology Heteroduplex Analysis/*methods Humans India/epidemiology Male Outpatient Clinics. P R Mehta PR Nema. 2010 Oct-Dec.com Mehta. Viral) IM AIDS Serodiagnosis Counseling DNA. N Ingole N Wanjare.4103/0255-0857. S Paranjpe S Ingole.

England TA . Paul AU . FAU .eng PT . Cape 7925. RESULTS: It was shown that irrespective of their CD4 counts both MUC5B and MUC7 from HIV patients. Corena AU . Anwar S AU .Journal Article PT . The purpose of this subsequent study was to investigate whether MUC5B and MUC7 from saliva of HIV patients or with full blown AIDS had a similar inhibitory ac tivity against the virus. Western blot and ELISA. Alth ough the reason for the inability of mucins from infected individuals to inhibi t the virus is not known.de Beer C FAU .Research Support. University of Cape Tow n.Mall.Department of Surgery.Lotz. and therefore of charge of mucin. Habtom H AU . in HIV positive patients.Virology journal JID .Habte HH FAU . Observatory. Western blot and ELISA respectively.Habte.20101014 PL . Non-U. AD . charge and immunoreacti vity differences between the mucins from HIV negative and positive individuals and among the mucins from HIV patients of different CD4 count was observed by SDS-PAGE. METHODS: Salivary MUC5B and MUC7 from HIV patients with different CD4 counts (< 200. it is likely that there is an alteration of the glycos ylation pattern.269 AB . Division of General Surgery. charge and immunoreactivity of mucins from HIV negative a nd positive individuals was also analysed by SDS-PAGE.BACKGROUND: We have previously shown that MUC5B and MUC7 mucins from saliv a of HIV negative individuals inhibit HIV-1 activity by 100% in an in vitro ass ay.PG . The size. Zoe E AU . CONCLUSIONS: Purified salivary mucins fr om HIV positive patients do not inhibit the AIDS virus in an in vitro assay. The a bility to inhibit the virus by aggregation by sugar chains is thus diminished.Mall AS LA . 200-400 and > 400) were incubated with HIV-1 prior to infection of the human T lymphoblastoid cell line (CEM SS cells).Virol J JT . did not inhibit HIV-1 activity. Size.101231645 .S. South Africa.Roux P FAU . Gov't DEP .de Beer.Roux. unlike the MUC5B and MUC7 from HIV negat ive individuals. Cells were then cultured and viral replication was measured by a qualitative p24 anti gen assay.Lotz ZE FAU .

RN RN RN RN RN RN SB MH MH MH MH MH MH MH MH MH MH MH MH MH MH ion PMC OID EDATMHDACRDTPHSTPHSTPHSTAID AID PST SO PMIDOWN STATDA DCOMIS IS VI IP DP TI - 0 (HIV Core Protein p24) 0 (MUC5B protein. As for other rapidly evolving pathogens of humans. The idea is to use viral RNA sequences obtained from pati ents . Western CD4 Lymphocyte Count Cell Line Electrophoresis. which indicates the control of the virus g enotype over this trait. human) 0 (Mucin-5B) 0 (Mucins) 0 (Salivary Proteins and Peptides) IM Blotting. human) 0 (MUC7 protein. 20941398 NLM MEDLINE 20101013 20110214 1553-7374 (Electronic) 1553-7366 (Linking) 6 9 2010 Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. the time of progression to AIDS. i. Polyacrylamide Gel Enzyme-Linked Immunosorbent Assay Female HIV Core Protein p24/analysis HIV Infections/*immunology HIV-1/*growth & development/*immunology Humans Molecular Weight Mucin-5B/chemistry/*immunology/isolation & purification Mucins/chemistry/*immunology/isolation & purification Salivary Proteins and Peptides/chemistry/*immunology/isolation & purificat PMC2967540 NLM: PMC2967540 2010/10/16 06:00 2010/12/14 06:00 2010/10/16 06:00 2010/05/11 [received] 2010/10/14 [accepted] 2010/10/14 [aheadofprint] 1743-422X-7-269 [pii] 10. 2010 Oct 14. it is difficu lt to know if this variance is controlled by the genotype of the host or that of the virus because the transmission chain is usually unknown.1186/1743-422X-7-269 [doi] epublish Virol J. LID .7:269.e1001123 [pii] AB .e. We apply the phylogenetic comparative approach (PCA) to estimate the heritability of a trait from one infection to the next.HIV virulence. varies greatly among patients.

Stadler T FAU . at least partially. Zurich.Yerly S FAU .Shah C FAU .Alizon S FAU . The approach reveals that up to half of the variance in set-point viral lo ad.Klimkait.cnrs.Bernasconi.Shah.Stadler. Andri AU .Boni.Hirschel B FAU .alizon@montp. Bernard AU .Boni J FAU .Rauch.Institute of Integrative Biology.Klimkait T FAU .Kouyos. Viktor AU . heritable from one infecti on to the next has clinical and epidemiological implications. The PCA opens new perspectives for approaches linking clinical data and evolutionary biology because it can be extended to study other traits or other infectious diseases. which can be applied to large datasets and accounts for within -host evolution. ETH Zurich. Tanja AU . Enos AU . Cyril AU . Hansjakob AU .Rauch A FAU . Thomas AU . Our estimate is signifi cant and robust to noise in the phylogeny. AD .Kouyos RD FAU .fr FAU . The difference bet ween earlier studies and ours comes from the quality of our dataset and from th e power of the PCA. Heritability is measured statistically as the prop ensity for patients close in the phylogeny to exhibit similar infection trait val ues. Sabine AU . Switzerland. can be heritable. samuel.Vernazza PL FAU .Alizon.Furrer. Jurg AU . Pietro L AU . Roger D AU .Battegay.Yerly.Battegay M . which approximately refl ects the transmission chain. a trait associated with virulence.von Wyl. we show the importance of taking into account the transmission chain when estimating correlations between infection traits. Manuel AU . Samuel AU .von Wyl V FAU .Vernazza.Bernasconi E FAU . We also check for the consistency of our approach by showing that a trait related to drug resistance is almost enti rely heritable. Finally. The fact that HIV virulence is.Hirschel.Furrer H FAU .infected by HIV-1 subtype B to build a phylogeny.

S. Non-U. Huldrych F Gunthard HF Bonhoeffer. Viral/genetics Viral Load/*genetics/*statistics & numerical data PMC2947993 NLM: PMC2947993 2010/10/14 06:00 2011/02/15 06:00 2010/10/14 06:00 2010/04/22 [received] 2010/08/27 [accepted] 2010/09/30 [epublish] 10.1371/journal.ppat. Burgisser.FAU AU FAU AU FAU AU FAU AU CN LA PT PT DEP PL TA JT JID RN RN SB MH MH MH MH MH MH MH MH MH MH PMC OID EDATMHDACRDTPHSTPHSTPHSTAID PST SO PMIDOWN STATDA DCOMIS IS VI DP TI PG AB g. S382-6 Host genome studies are increasingly available for the study of infectious disease susceptibility.6(9). Philippe Burgisser P Telenti. Gov't 20100930 United States PLoS Pathog PLoS pathogens 101238921 0 (Anti-HIV Agents) 0 (RNA. pii: e1001123. These appr oaches . Current technologies include large-scale genotypin genome-wide screens such as transcriptome and silencing (silencing RNA) st udies. Statistical *Phylogeny Quantitative Trait Loci RNA. Viral) IM Anti-HIV Agents/therapeutic use Genotype HIV Infections/drug therapy/*genetics/*transmission HIV-1/*classification/*genetics Humans Models. 20887229 NLM MEDLINE 20101004 20101101 1537-6613 (Electronic) 0022-1899 (Linking) 202 Suppl 3 2010 Nov 1 Genomic approaches to the study of HIV-1 acquisition. and increasingly. Sebastian Bonhoeffer S Swiss HIV Cohort Study eng Journal Article Research Support. the possibility to sequence complete genomes. 2010 Sep 30. Amalio Telenti A Gunthard.1001123 [doi] epublish PLoS Pathog.

United States TA .AIM SB .ppublish SO . The pattern of enrichment for CCR5 Delta32 homozy gosis should serve as the standard for assessing the extent to which a given coh ort (of white subjects) includes a large proportion of exposed uninfected individu als.Telenti. or "HIV-1-resistant" individuals.J Infect Dis.Since the late 1980s.*Genetic Predisposition to Disease MH .Humans EDAT.10.IM MH .telenti@chuv.Gene Expression Profiling MH .The Journal of infectious diseases JID .HIV-1/*immunology MH .J Infect Dis JT .1086/655969 [doi] PST .S.2010/11/03 06:00 CRDT. 2010 Nov 1.2010/10/05 06:00 AID .Gene Silencing MH . Paul AU .eng PT . amalio. PG .McLaren P LA . Non-U.0413675 SB .2010/10/05 06:00 MHDA.Genetic Testing/methods MH . Amalio AU . The main limit ation remains the ascertainment of exposure and establishing large cohorts of informative individuals.Review PL .Institute of Microbiology.Research Support. Switzerland. University Hospital Center. with the first identification of individuals who wer e exposed to human immunodeficiency virus type 1 (HIV-1) yet remained uninfe cted.McLaren.are of interest for the study of individuals who remain uninfected despite documented exposure to human immunodeficiency virus type 1.ch FAU .HIV Infections/*genetics/virology MH . University of Lausa nne. Lausanne.Journal Article PT . PMIDOWN STATDA DCOMIS IS VI DP TI s and 20887228 NLM MEDLINE 20101004 20101101 1537-6613 (Electronic) 0022-1899 (Linking) 202 Suppl 3 2010 Nov 1 Cohorts for the study of HIV-1-exposed but uninfected individuals: benefit limitations. AD .202 Suppl 3:S382-6.Telenti A FAU .S377-81 AB . Gov't PT . a large number of cohorts that include HIV-exposed seronegative (HESN) subjects have been identified globally for .

IM MH . K AU .0413675 SB .Review PL . T Blake AU .2010/10/05 06:00 MHDA. S361-5 . Innate MH . Canada.McLaren PJ FAU .Horton RE FAU .Fowke K FAU .the purpose of investigating the genetic. R E AU .HIV-1/*immunology MH .Kimani.Journal Article PT .10. In this article.AIM SB .Department of Medical Microbiology.HIV Infections/*immunology/*transmission MH .Male MH .2010/11/03 06:00 CRDT. PMIDOWN STATDA DCOMIS IS VI DP TI PG 20887225 NLM MEDLINE 20101004 20101101 1537-6613 (Electronic) 0022-1899 (Linking) 202 Suppl 3 2010 Nov 1 Innate immunity in resistance to HIV infection. Gov't PT .2010/10/05 06:00 AID . AD . Non-U.Disease Susceptibility MH .McLaren.Research Support. Mani toba. in light of the r ecent International Symposium on Natural Immunity to HIV.Horton.1086/655971 [doi] PST .J Infect Dis JT .Humans MH .ppublish SO . 2010 Nov 1.eng PT . Winnipeg.Risk Factors EDAT.Ball TB LA . FAU . we review the characte ristics of different groups with respect to their relative risks and briefly summa rize the known cohorts that include exposed uninfected subjects worldwide.S.The Journal of infectious diseases JID .Fowke.202 Suppl 3:S377-81. P J AU .*Immunity. University of Manitoba.United States TA .Ball.Kimani J FAU .Female MH . immunologic.Cohort Studies MH . and environmental facto rs that may help alter susceptibility to HIV-1. J AU .J Infect Dis.

2010/10/05 06:00 MHDA.4.HIV/*immunology MH . but many recently published articles suggest a key role for Toll&#x2010.202 Suppl 3:S361-5.like receptors.Biasin. Luca AU .Interleukins/immunology MH .phase amyloid A protein.22. and APOBEC3G in conferring resistance to HIV infection.infected individuals depends on multiple factors involv ing both the innate and the adaptive immune system.HIV Infections/*immunology MH . Italy. Non-U. The study of these factors will shed light on HIV pathogenesis and contribute to the development of new therapeutic approaches to this elusive disease. University of Milano.Clerici.Resistance to human immunodeficiency virus (HIV) infection in subjects who do not seroconvert despite multiple exposures to the virus and to the progression to AIDS in HIV&#x2010.Cytidine Deaminase/immunology MH .10.2010/11/03 06:00 CRDT.Humans MH . PMIDOWN STATDA 20887224 NLM MEDLINE 20101004 . The contribution of natura l immunity in preventing HIV infection has so far received little attention. mara. Gov't PL .1086/655965 [doi] PST .Research Support.J Infect Dis JT .AB .5 (Cytidine Deaminase) SB .biasin@unimi.0 (Interleukins) RN .ppublish SO .it FAU .0 (Serum Amyloid A Protein) RN .0413675 RN .Serum Amyloid A Protein/immunology MH . Milan.United States TA .5 (APOBEC3G protein.Piacentini. Natural/immunology MH .0 (Toll-Like Receptors) RN .Journal Article PT . 2010 Nov 1.*Immunity.2010/10/05 06:00 AID .Biasin M FAU .4.0 (interleukin-22) RN .5. human) RN .The Journal of infectious diseases JID .Toll-Like Receptors/immunology EDAT.eng PT .Department of Clinical Sciences. Mario AU .Killer Cells. Innate MH .Piacentini L LA . acute&#x2010.S.EC 3.J Infect Dis. natural killer cells. interleukin&#x2010.IM MH .AIM SB . AD .5.EC 3. Mara AU .Clerici M FAU .

0413675 RN .Several combinations of genes encoding KIR3DL1 alleles and their HLA-Bw4 l igands have been linked with favorable outcomes upon exposure to or infection wit h human immunodeficiency virus (HIV).Parsons.Bruneau. AD . Julie AU .Shoukry NH FAU . KIR3DL1*004/HL A-Bw4 is not associated with a reduced risk of infection.DCOMIS IS VI DP TI ral 20101101 1537-6613 (Electronic) 0022-1899 (Linking) 202 Suppl 3 2010 Nov 1 Mind the gap: lack of association between KIR3DL1*004/HLA-Bw4-induced natu killer cell function and protection from HIV infection. Montreal.0 (HLA-Bw4) RN .Boulet.Bruneau J FAU . Non-U. Nicole F AU . Naglaa H AU . Jean-Pierre AU . Matthew S AU .0 (Receptors. The K562-stimulate d functionality of NK cells from KIR3DL1*004/HLA-Bw4 and control genotype ca rriers was assessed by flow cytometry and found to be higher in KIR3DL1*004/HLA-B w4 carriers.HVI 79515/Canadian Institutes of Health Research/Canada PT . However.Boulet S FAU . Rujun AU .S356-60 AB .IM . Thus.Tsoukas CM FAU . Canada.Routy JP FAU .Research Institute of the McGill University Health Centre.Routy. PG . a comparison of the frequency of this combined genotype among HIV-exposed uninfected and HIV-infected subjects revealed no between-group differences. FAU . human) RN .0 (KIR3DL1 protein.AIM SB . Salix AU .J Infect Dis JT . despite its ability to license NK cells. Christos M AU .Shoukry. KIR3DL1) SB .Tsoukas.eng GR .0 (HLA-B Antigens) RN . Some protective KIR3DL1/HLA-Bw4 combinations confer elevated natural killer (NK) cell functional potential.Bernard.United States TA .Bernard NF LA .Journal Article PT .Song R FAU .Parsons MS FAU .The Journal of infectious diseases JID . Gov't PL .S.Research Support.Song. Quebe c.

PG .Broliden K LA .Journal Article PT . Infectious Disease Unit. To complicate the picture. Gov't .Department of Medicine.S351-5 AB . Solna.se FAU .Sexual transmission is the single most common mechanism for acquiring infe ction with human immunodeficiency virus (HIV). Studies in muc osal samples of HIV&#x2010.Research Support.Broliden. 20887223 NLM MEDLINE 20101004 20101101 1537-6613 (Electronic) 0022-1899 (Linking) 202 Suppl 3 2010 Nov 1 Innate molecular and anatomic mucosal barriers against HIV infection in th genital tract of HIV-exposed seronegative individuals. and the efficiency of transmissio n reflects the biology of the mucosal site. 2010 Nov 1. Kristina. Non-U. hormones. Sweden.1086/655966 [doi] ppublish J Infect Dis.exposed seronegative individuals are among the many opportunities to explore the biological events of HIV transmission under physiological circumstances.eng PT .MH MH MH MH MH MH MH MH EDATMHDACRDTAID PST SO PMIDOWN STATDA DCOMIS IS VI DP TI e Gene Frequency HIV/*immunology HIV Infections/*genetics/*immunology HLA-B Antigens/*genetics Humans *Immunity.broliden@karolinska. Natural/*immunology Receptors. and time points. AD .202 Suppl 3:S356-60. Considerin g the additional physiological changes induced by inflammation. concentrations. Karolinska University Hospital. KIR3DL1/*genetics 2010/10/05 06:00 2010/11/03 06:00 2010/10/05 06:00 10. Kristina AU . it is an enormous challenge to design relevant experimental mo dels for evaluating prophylactic compounds or biological events. and se men deposition. Karolinska Institutet.S. The localization and phenotypic characterization of HIV target cells and receptors and the presence of imm une molecules are therefore important to define at sites of HIV exposure. Center for Molecul ar Medicine. HIV&#x2010. Stockholm .binding receptors and antiviral immune molecules can be protective under certain circumstances but can exert an o pposite effect at other mucosal sites. Innate Killer Cells.

20101101 IS . Gianfranco . gianfranco.fr FAU .0022-1899 (Linking) VI . PMID.pancino@pasteur. associated with low levels of CD4+ T cell activa tion in vivo and/or cell restriction of viral replication.202 Suppl 3 DP .Natural resistance to HIV infection: lessons learned from HIV-exposed unin fected individuals. Scientific and ethical is sues encountered during research in exposed uninfected subjects must be conside red. PG . These results support a contribution of inn ate responses to resistance against HIV-1 infection. associated with increased ratios of activating to inhibitor y natural killer cell receptors. Paris.20101004 DCOM.2010 Nov 1 TI .1086/655964 [doi] ppublish J Infect Dis. and enhanced natural ki ller cell activity.MEDLINE DA .202 Suppl 3:S351-5.Pancino.Institut Pasteur. AD .PL TA JT JID SB SB MH MH MH MH MH MH MH MH EDATMHDACRDTAID PST SO - United States J Infect Dis The Journal of infectious diseases 0413675 AIM IM Female Genitalia/*anatomy & histology/*immunology HIV/*immunology HIV Infections/*immunology/transmission Humans *Immunity. Innate Male Mucous Membrane/*anatomy & histology/*immunology 2010/10/05 06:00 2010/11/03 06:00 2010/10/05 06:00 10. Our mai n findings were reduced susceptibility of peripheral blood mononuclear cells to HIV-1 infection in vitro. Unite de Regulation des Infections Retrovirales. France.1537-6613 (Electronic) IS .NLM STAT.S345-50 AB . 2010 Nov 1.20887222 OWN .We explored potential mechanisms of resistance to human immunodeficiency v irus type 1 (HIV-1) infection in different groups of uninfected individuals exp osed by systemic or mucosal routes: intravascular drug users in Vietnam and spouse s of HIV-infected individuals in Cambodia and Central African Republic.

20887221 OWN . Non-U.2010 Nov 1 TI . Asier Saez-Cirion A Scott-Algara.MEDLINE DA . We also showed that CD4+ T cells of HIV-exposed seronegative commercial sex worker s have a characteristically lower level of gene expression that can be seen in differentially expressed genes and systems crucial for HIV replication. Gov't United States J Infect Dis The Journal of infectious diseases 0413675 AIM IM Cambodia Central African Republic Female HIV Infections/*immunology HIV-1/*immunology Humans *Immunity. In the present study we demonstrated that HIV-exposed seronegative commercial sex workers produce lower levels of proinflammatory cytokines at baseline than HIV-negative control subjects.HIV-exposed seronegative commercial sex workers show a quiescent phenotype in the CD4+ T cell compartment and reduced expression of HIV-dependent host facto rs. Innate Killer Cells.202 Suppl 3 DP . Pascale Paul P eng Journal Article Research Support.AU FAU AU FAU AU FAU AU LA PT PT PL TA JT JID SB SB MH MH MH MH MH MH MH MH MH MH MH MH EDATMHDACRDTAID PST SO - Pancino G Saez-Cirion. 2010 Nov 1. Daniel Scott-Algara D Paul.1537-6613 (Electronic) IS . Natural/immunology Leukocytes.Studies of human immunodeficiency virus (HIV)-exposed seronegative individ uals are crucial to inform vaccine design. PMID.S.NLM STAT.20101004 DCOM.0022-1899 (Linking) VI .20101101 IS . Mononuclear/*immunology/*virology Lymphocyte Activation Male Vietnam 2010/10/05 06:00 2010/11/03 06:00 2010/10/05 06:00 10.1086/655973 [doi] ppublish J Infect Dis.202 Suppl 3:S345-50. PG .S339-44 AB . su .

Paul J AU .*Gene Expression MH .CD4-Positive T-Lymphocytes/*immunology/*virology MH .Plummer. Canad a.HIV/*immunology MH . Gov't PL .2010/10/05 06:00 MHDA.Jaoko. Joshua AU .Danesh A FAU . Ali AU . Non-U.eng GR .Fowke.IM MH .Plummer FA FAU .Department of Medical Microbiology.McLaren.HIV Infections/*immunology MH . 2010 Nov 1.Fowke KR LA . FAU .Ball.0413675 RN . David J AU .ch as the T cell receptor pathway and previously identified HIV dependency facto rs.202 Suppl 3:S339-44. AD . Walter AU .Jaoko W FAU . T Blake AU .AIM SB .J Infect Dis.McLaren PJ FAU .Cytokines/*blood MH .Kimani.Phenotype MH . Ontario. Charles AU .Kelvin.MDP-86721/Canadian Institutes of Health Research/Canada PT .HOP-75348/Canadian Institutes of Health Research/Canada GR .ppublish SO . This apparent lowered activation results in a phenomenon we term "immune quiescence.0 (Cytokines) SB ." which may contribute to host resistance to HIV.Wachihi C FAU .10. PMIDOWN STATDA DCOMIS IS 20887220 NLM MEDLINE 20101004 20101101 1537-6613 (Electronic) 0022-1899 (Linking) .1086/655968 [doi] PST .Kelvin DJ FAU . Keith R AU . University of Manitoba.Journal Article PT .Ball TB FAU .2010/11/03 06:00 CRDT.Female MH .Prostitution EDAT.Research Support.2010/10/05 06:00 AID .Danesh. Francis A AU .Kimani J FAU .J Infect Dis JT .S.The Journal of infectious diseases JID .Humans MH .Wachihi.United States TA .

risk uninfected cohorts. In these cohorts a variety of characteristics have been pro posed as mediating protection.Anthony.Lederman MM FAU . cohorts of uninfected persons have been reported who are considered at hig h risk for infection. OH 44106. there are probably many other factors that may individually or in combination provid e some level of protection from acquisition of HIV infection. Galit AU . University Hospitals/Case Medical Center. Aaron AU .Harding.Anthony D FAU .Hardy. Michael M AU .edu FAU .VI DP TI view. Benigno AU . but to date only the 32&#x2013. MXL6@c ase.Weinberg. Donald AU .Alter G FAU .Silverman. Michael AU . has been associated with high&#x2010.base pair deletion in the chemokine (C&#x2010. identifying them with confidence will be difficult. With this in mind.Weinberg A FAU .Center for AIDS Research. PG AB me ion 202 Suppl 3 2010 Nov 1 Determinants of protection among HIV-exposed seronegative persons: an over S333-8 Both clinical experience and a growing medical literature indicate that so persons who have been exposed to human immunodeficiency virus (HIV) infect remain uninfected. who shou ld undergo targeted studies of plausible mediators and broad screening for unexpected determinants of protection.Daskalakis.Daskalakis DC FAU . AD .Sieg.Hardy G FAU . clarifyin g the determinants of protection against HIV infection is a high priority that w ill require careful selection of high&#x2010. which results in complete fa ilure of cell surface expression of this coreceptor.Harding C FAU . Nonetheless. Case Western Reserve University School of Medici ne. Demetre C AU . Cleveland.Rodriguez B FAU . USA. Gareth AU . Scott F AU . Clifford AU .C motif) receptor 5 gene.Sieg SF FAU . Although in some instances this may represent good fort une.Rodriguez.Lederman. Because some of the se factors are probably incompletely protective or inconsistently active. Robert H .level protection from HIV infection.Alter.Cho M FAU .Cho.

Daniel C Douek DC Margolis. CCR5) 0 (Receptors. HIV) AIM IM HIV/*immunology HIV Infections/*genetics/*immunology Humans *Immunity.Multiple and frequent exposure to the human immunodeficiency virus (HIV) d oes not necessarily result in HIV infection. Approximately 15% of HIV exposed seronegative individuals repeatedly resist infection.S329-32 AB .S. Mary Carrington M Goedert. Non-U. a phenomenon that ha s been observed in all investigated HIV&#x2010. CCR5/genetics Receptors. This brief report provides a limited historic perspective of the discovery of these cohorts and outlines some of the immunologic and genetic parameters that are associate d with resistance. We raise the possibility that assessing immunologic parameters .exposed cohorts. David B Goldstein DB Carrington.AU FAU AU FAU AU FAU AU FAU AU FAU AU LA PT PT PT PL TA JT JID RN RN SB SB MH MH MH MH MH MH EDATMHDACRDTAID PST SO PMIDOWN STATDA DCOMIS IS VI DP TI done Silverman RH Douek. Leonid Margolis L Goldstein. Innate Receptors.202 Suppl 3:S333-8. 20887219 NLM MEDLINE 20101004 20101101 1537-6613 (Electronic) 0022-1899 (Linking) 202 Suppl 3 2010 Nov 1 Historical perspective on HIV-exposed seronegative individuals: has nature the experiment for us? PG . HIV/genetics 2010/10/05 06:00 2010/11/03 06:00 2010/10/05 06:00 10. Gov't Review United States J Infect Dis The Journal of infectious diseases 0413675 0 (Receptors. James J Goedert JJ eng Journal Article Research Support.1086/655967 [doi] ppublish J Infect Dis. 2010 Nov 1.

10. AD . 20th Century MH .Shearer G FAU .HIV Infections/genetics/*history/*immunology/transmission MH .1086/655974 [doi] PST .History.Humans MH . N.eng PT .Disease Susceptibility MH .IM MH .I. Maryland.Experimental immunology Branch. National Cancer Institute.2010/11/03 06:00 CRDT.History.AIM SB . USA..Shearer.2010/10/05 06:00 AID . FAU .*Immunity.ppublish SO .Cohort Studies MH .S.Clerici.Clerici M LA .202 Suppl 3:S329-32. Gov't PT .Research Support. .Journal Article PT . Intramural PT .J Infect Dis JT .H. Bethesda.2010/10/05 06:00 MHDA.Research Support. Innate MH . Gene AU .United States TA .Review PL . 2010 Nov 1. 21st Century MH .of the phenomenon might provide insights that might be relevant for effective AID S vaccine design. National Instit utes of Health. Non-U.HIV-1/*immunology MH .Risk Factors EDAT. Mario AU .Historical Article PT .0413675 SB .J Infect Dis.The Journal of infectious diseases JID .